{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:55:39Z","timestamp":1793307339892,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["22YF1426500"],"award-info":[{"award-number":["22YF1426500"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Shanghai Municipality","award":["23ZR1439500"],"award-info":[{"award-number":["23ZR1439500"]}]},{"DOI":"10.13039\/100020732","name":"Innovative Research Team of High-level Local University in Shanghai","doi-asserted-by":"crossref","award":["SHSMU-ZDCX20212200"],"award-info":[{"award-number":["SHSMU-ZDCX20212200"]}],"id":[{"id":"10.13039\/100020732","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-92872-2","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T07:43:38Z","timestamp":1742629418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development and validation of a postoperative prognostic model for hormone receptor positive early stage breast cancer recurrence"],"prefix":"10.1038","volume":"15","author":[{"given":"Ruixin","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoting","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunwei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"issue":"1","key":"92872_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA A Cancer J. Clin. 74(1), 12\u201349. https:\/\/doi.org\/10.3322\/caac.21820 (2024).","journal-title":"CA A Cancer J. Clin."},{"issue":"6","key":"92872_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto, A. N. et al. Breast cancer statistics, 2022. CA Cancer J. Clin. 72(6), 524\u2013541. https:\/\/doi.org\/10.3322\/caac.21754 (2022).","journal-title":"CA Cancer J. Clin."},{"issue":"19","key":"92872_CR3","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan, H. et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 377(19), 1836\u20131846. https:\/\/doi.org\/10.1056\/NEJMoa1701830 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"92872_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon, D. et al. Ribociclib plus endocrine therapy in early breast cancer. N. Engl. J. Med. 390(12), 1080\u20131091. https:\/\/doi.org\/10.1056\/NEJMoa2305488 (2024).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"92872_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston, S. R. D. et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): Results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 24(1), 77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(22)00694-5 (2023).","journal-title":"Lancet Oncol."},{"issue":"9","key":"92872_CR6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"P Rastogi","year":"2024","unstructured":"Rastogi, P. et al. adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: Results from a preplanned monarche overall survival interim analysis, including 5-year efficacy outcomes. J. Clin. Oncol. 42(9), 987\u2013993. https:\/\/doi.org\/10.1200\/JCO.23.01994 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"92872_CR7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.21.02554","volume":"40","author":"M Gnant","year":"2022","unstructured":"Gnant, M. et al. Adjuvant palbociclib for early breast cancer: The PALLAS Trial Results (ABCSG-42\/AFT-05\/BIG-14-03). J. Clin. Oncol. 40(3), 282\u2013293. https:\/\/doi.org\/10.1200\/JCO.21.02554 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"92872_CR8","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky, K. et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N. Engl. J. Med. 385(25), 2336\u20132347. https:\/\/doi.org\/10.1056\/NEJMoa2108873 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"92872_CR9","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","volume":"22","author":"M Piccart","year":"2021","unstructured":"Piccart, M. et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 22(4), 476\u2013488. https:\/\/doi.org\/10.1016\/S1470-2045(21)00007-3 (2021).","journal-title":"Lancet Oncol."},{"issue":"8","key":"92872_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso, F. et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N. Engl. J. Med. 375(8), 717\u2013729. https:\/\/doi.org\/10.1056\/NEJMoa1602253 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"92872_CR11","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2017.76.4258","volume":"36","author":"M Dowsett","year":"2018","unstructured":"Dowsett, M. et al. Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5. J. Clin. Oncol. 36(19), 1941\u20131948. https:\/\/doi.org\/10.1200\/JCO.2017.76.4258 (2018).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"92872_CR12","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1186\/bcr2464","volume":"12","author":"GC Wishart","year":"2010","unstructured":"Wishart, G. C. et al. PREDICT: A new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 12(1), R1. https:\/\/doi.org\/10.1186\/bcr2464 (2010).","journal-title":"Breast Cancer Res."},{"issue":"11","key":"92872_CR13","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1470-2045(09)70254-2","volume":"10","author":"S Mook","year":"2009","unstructured":"Mook, S. et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: A hospital-based retrospective cohort study. Lancet Oncol. 10(11), 1070\u20131076. https:\/\/doi.org\/10.1016\/S1470-2045(09)70254-2 (2009).","journal-title":"Lancet Oncol."},{"issue":"4","key":"92872_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3322\/caac.21393","volume":"67","author":"AE Giuliano","year":"2017","unstructured":"Giuliano, A. E. et al. Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Cancer J. Clin. 67(4), 290\u2013303. https:\/\/doi.org\/10.3322\/caac.21393 (2017).","journal-title":"Cancer J. Clin."},{"key":"92872_CR15","doi-asserted-by":"publisher","first-page":"g7594","DOI":"10.1136\/bmj.g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins, G. S., Reitsma, J. B., Altman, D. G. & Moons, K. G. M. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. BMJ 350, g7594. https:\/\/doi.org\/10.1136\/bmj.g7594 (2015).","journal-title":"BMJ"},{"issue":"24","key":"92872_CR16","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1200\/JCO.20.03613","volume":"39","author":"SM Tolaney","year":"2021","unstructured":"Tolaney, S. M. et al. Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP Version 2.0. JCO 39(24), 2720\u20132731. https:\/\/doi.org\/10.1200\/JCO.20.03613 (2021).","journal-title":"JCO"},{"issue":"4","key":"92872_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White, I. R., Royston, P. & Wood, A. M. Multiple imputation using chained equations: Issues and guidance for practice. Stat. Med. 30(4), 377\u2013399. https:\/\/doi.org\/10.1002\/sim.4067 (2011).","journal-title":"Stat. Med."},{"key":"92872_CR18","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonreponse in Surveys","author":"DB Rubin","year":"1987","unstructured":"Rubin, D. B. Multiple Imputation for Nonreponse in Surveys (Wiley, Hoboken, 1987)."},{"key":"#cr-split#-92872_CR19.1","unstructured":"Gorishniy, Y., Rubachev, I., Khrulkov, V. & Babenko, A. Revisiting Deep Learning Models for Tabular Data. (2023)"},{"key":"#cr-split#-92872_CR19.2","unstructured":"(arXiv:2106.11959). Accessed September 23, 2024. http:\/\/arxiv.org\/abs\/2106.11959."},{"issue":"18","key":"92872_CR20","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1002\/sim.6152","volume":"33","author":"TA Gerds","year":"2014","unstructured":"Gerds, T. A., Andersen, P. K. & Kattan, M. W. Calibration plots for risk prediction models in the presence of competing risks. Stat. Med. 33(18), 3191\u20133203. https:\/\/doi.org\/10.1002\/sim.6152 (2014).","journal-title":"Stat. Med."},{"issue":"6","key":"92872_CR21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers, A. J. & Elkin, E. B. Decision curve analysis: A novel method for evaluating prediction models. Med. Decis. Mak. 26(6), 565\u2013574. https:\/\/doi.org\/10.1177\/0272989X06295361 (2006).","journal-title":"Med. Decis. Mak."},{"issue":"5","key":"92872_CR22","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/s41591-024-02905-y","volume":"30","author":"J Hippisley-Cox","year":"2024","unstructured":"Hippisley-Cox, J. et al. Development and validation of a new algorithm for improved cardiovascular risk prediction. Nat. Med. 30(5), 1440\u20131447. https:\/\/doi.org\/10.1038\/s41591-024-02905-y (2024).","journal-title":"Nat. Med."},{"issue":"10","key":"92872_CR23","doi-asserted-by":"publisher","first-page":"e663","DOI":"10.1016\/S2666-7568(21)00179-3","volume":"2","author":"Y Van Herck","year":"2021","unstructured":"Van Herck, Y. et al. Is cancer biology different in older patients?. Lancet Healthy Longev. 2(10), e663\u2013e677. https:\/\/doi.org\/10.1016\/S2666-7568(21)00179-3 (2021).","journal-title":"Lancet Healthy Longev."},{"issue":"1","key":"92872_CR24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12885-020-6684-z","volume":"20","author":"NE Mealey","year":"2020","unstructured":"Mealey, N. E. et al. Mutational landscape differences between young-onset and older-onset breast cancer patients. BMC Cancer 20(1), 212. https:\/\/doi.org\/10.1186\/s12885-020-6684-z (2020).","journal-title":"BMC Cancer"},{"issue":"1","key":"92872_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ijc.2910590105","volume":"59","author":"S Romain","year":"1994","unstructured":"Romain, S., Chinot, O., Guirou, O., Soulli\u00e8re, M. & Martin, P. Biological heterogeneity of er-positive breast cancers in the post-menopausal population. Int. J. Cancer 59(1), 17\u201319. https:\/\/doi.org\/10.1002\/ijc.2910590105 (1994).","journal-title":"Int. J. Cancer"},{"key":"92872_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.breast.2021.02.009","volume":"57","author":"EM Salvo","year":"2021","unstructured":"Salvo, E. M. et al. Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis. Breast 57, 5\u201317. https:\/\/doi.org\/10.1016\/j.breast.2021.02.009 (2021).","journal-title":"Breast"},{"issue":"10001","key":"92872_CR27","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001), 1341\u20131352. https:\/\/doi.org\/10.1016\/S0140-6736(15)61074-1 (2015).","journal-title":"Lancet"},{"issue":"1","key":"92872_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10549-015-3666-y","volume":"155","author":"V Sopik","year":"2016","unstructured":"Sopik, V., Nofech-Mozes, S., Sun, P. & Narod, S. A. The relationship between local recurrence and death in early-stage breast cancer. Breast Cancer Res. Treat. 155(1), 175\u2013185. https:\/\/doi.org\/10.1007\/s10549-015-3666-y (2016).","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"92872_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/bcr2607","volume":"12","author":"EA Rakha","year":"2010","unstructured":"Rakha, E. A. et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 12(4), 207. https:\/\/doi.org\/10.1186\/bcr2607 (2010).","journal-title":"Breast Cancer Res."},{"issue":"10","key":"92872_CR30","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1093\/annonc\/mdz189","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso, F. et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30(10), 1674. https:\/\/doi.org\/10.1093\/annonc\/mdz189 (2019).","journal-title":"Ann. Oncol."},{"issue":"2","key":"92872_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.5152\/ejbh.2019.4414","volume":"15","author":"F Tonellotto","year":"2019","unstructured":"Tonellotto, F. et al. Impact of number of positive lymph nodes and lymph node ratio on survival of women with node-positive breast cancer. Eur. J. Breast Health 15(2), 76\u201384. https:\/\/doi.org\/10.5152\/ejbh.2019.4414 (2019).","journal-title":"Eur. J. Breast Health"},{"issue":"5","key":"92872_CR32","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/annonc\/mdm001","volume":"18","author":"L Mauriac","year":"2007","unstructured":"Mauriac, L. et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1\u201398 trial. Ann. Oncol. 18(5), 859\u2013867. https:\/\/doi.org\/10.1093\/annonc\/mdm001 (2007).","journal-title":"Ann. Oncol."},{"issue":"8","key":"92872_CR33","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","volume":"28","author":"G Curigliano","year":"2017","unstructured":"Curigliano, G. et al. De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann. Oncol. 28(8), 1700\u20131712. https:\/\/doi.org\/10.1093\/annonc\/mdx308 (2017).","journal-title":"Ann. Oncol."},{"issue":"4","key":"92872_CR34","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/SLA.0000000000005064","volume":"274","author":"R Weiser","year":"2021","unstructured":"Weiser, R. et al. De-escalation of endocrine therapy in early hormone receptor-positive breast cancer: When is local treatment enough?. Ann. Surg. 274(4), 654\u2013663. https:\/\/doi.org\/10.1097\/SLA.0000000000005064 (2021).","journal-title":"Ann. Surg."},{"key":"92872_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/EDBK_350358","volume":"42","author":"B Pistilli","year":"2022","unstructured":"Pistilli, B., Lohrisch, C., Sheade, J. & Fleming, G. F. Personalizing adjuvant endocrine therapy for early-stage hormone receptor-positive breast cancer. Am. Soc. Clin. Oncol. Educ. Book 42, 60\u201372. https:\/\/doi.org\/10.1200\/EDBK_350358 (2022).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"6","key":"92872_CR36","doi-asserted-by":"publisher","first-page":"e206368","DOI":"10.1001\/jamanetworkopen.2020.6368","volume":"3","author":"FM Howard","year":"2020","unstructured":"Howard, F. M. & Pearson, A. T. Prognosis and Treatment of non-small cell lung cancer in the age of deep learning. JAMA Netw. Open 3(6), e206368. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.6368 (2020).","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"92872_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12874-018-0482-1","volume":"18","author":"JL Katzman","year":"2018","unstructured":"Katzman, J. L. et al. DeepSurv: Personalized treatment recommender system using a Cox proportional hazards deep neural network. BMC Med. Res. Methodol. 18(1), 24. https:\/\/doi.org\/10.1186\/s12874-018-0482-1 (2018).","journal-title":"BMC Med. Res. Methodol."},{"key":"92872_CR38","doi-asserted-by":"publisher","first-page":"e073800","DOI":"10.1136\/bmj-2022-073800","volume":"381","author":"AK Clift","year":"2023","unstructured":"Clift, A. K. et al. Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study. BMJ 381, e073800. https:\/\/doi.org\/10.1136\/bmj-2022-073800 (2023).","journal-title":"BMJ"},{"key":"92872_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/BCTT.S35581","volume":"5","author":"C Taylor","year":"2013","unstructured":"Taylor, C., Shewbridge, A., Harris, J. & Green, J. S. Benefits of multidisciplinary teamwork in the management of breast cancer. Breast Cancer (Dove Med Press) 5, 79\u201385. https:\/\/doi.org\/10.2147\/BCTT.S35581 (2013).","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"1","key":"92872_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-020-0167-z","volume":"6","author":"N Harbeck","year":"2020","unstructured":"Harbeck, N. Breast cancer is a systemic disease optimally treated by a multidisciplinary team. Nat. Rev. Dis. Primers 6(1), 30. https:\/\/doi.org\/10.1038\/s41572-020-0167-z (2020).","journal-title":"Nat. Rev. Dis. Primers"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92872-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92872-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92872-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T07:43:50Z","timestamp":1742629430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92872-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["92872"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-92872-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethical Review Boards of Ruijin Hospital (No. 2023126). All participants included in this study signed the informed consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"9905"}}